Why Are BCAAs in a Brain Supplement? What the Evidence Does and Doesn't Support

What BCAAs actually do at the blood-brain barrier

Start with the part that is genuinely well established, because it is the reason anyone thought to put these amino acids in a brain formula in the first place.

Leucine, isoleucine and valine are large neutral amino acids. So are tryptophan, tyrosine and phenylalanine. All six cross into the brain on the same carrier: the large neutral amino acid transporter LAT1, encoded by SLC7A5 and sitting in the endothelial cells of the blood-brain barrier. LAT1 has a finite number of seats, and it does not care which molecule takes them. Transport is competitive.

John Fernstrom laid this out in a 2005 review in the Journal of Nutrition. When plasma BCAA concentrations rise, brain BCAA levels rise with them — and brain concentrations of the aromatic amino acids fall, because they have lost the competition for the transporter. That matters because tryptophan is the precursor for serotonin and tyrosine is the precursor for dopamine and noradrenaline. Push more BCAAs into the bloodstream and you can, in principle, nudge down the raw material for two major neurotransmitter systems.

Read that carefully, because it is a two-edged mechanism and the supplement industry usually presents only one edge. "BCAAs influence brain neurotransmitters" is true. It does not follow that they influence them in a helpful direction. Fernstrom's own conclusion was that dose-response relationships and the threshold for adverse effects both needed more research — a striking thing to have to say about a nutrient sold by the tub.

Where the human cognitive evidence actually comes from

Search for human trials of BCAAs and cognition and you land almost immediately in a hospital. This is the single most important fact about this ingredient and it is the one no product page will tell you.

Severe traumatic brain injury depletes circulating and brain BCAA levels, and BCAAs are precursors for glutamate synthesis. That gave a plausible clinical rationale, and two small Italian randomised trials tested it. Both came from Aquilani and colleagues — a 2005 trial in severe traumatic brain injury and a 2008 pilot in vegetative or minimally conscious patients — both were published in Archives of Physical Medicine and Rehabilitation, and both infused 19.6 grams of BCAAs a day intravenously for 15 days.

Where the evidence comes from, and whether it transfers

The bottom row is the whole story. It is not that the evidence is negative. It is that for the specific question a shopper is asking — will this help me think more clearly — nobody has run the experiment.

It is also worth noting what the reviewers made of the injury data. The US Institute of Medicine assessed BCAAs for its report Nutrition and Traumatic Brain Injury, examined exactly this literature, and concluded there were "not yet compelling data to support a recommendation to supplement rations with BCAAs to ameliorate or treat TBI." If the evidence is judged insufficient for the population it was collected in, it cannot support a stronger claim in a population it was never collected in.

The central fatigue hypothesis, and why it did not settle the question

The other place BCAAs and the brain meet is sports science. During prolonged exercise, plasma BCAA levels fall as muscle takes them up, while free tryptophan rises. The ratio shifts, more tryptophan wins the LAT1 competition, brain serotonin rises, and the athlete feels tired. That is the central fatigue hypothesis, and supplementing BCAAs was the obvious way to test it.

The biochemistry behaves as predicted. Supplemental BCAAs do blunt the shift in the tryptophan-to-BCAA ratio. The performance results are another matter: human trials have been inconsistent, methodologically mixed, and considerably less impressive than the rodent work showing dietary BCAAs ease injury-induced cognitive impairment. Reviews of the serotonin hypothesis of central fatigue have repeatedly concluded that the evidence for a decisive serotonergic role in fatigue remains unconvincing.

This is a useful cautionary tale for anyone reading a nootropic label. A mechanism can be demonstrably real, measurable in blood, and still fail to produce a reliable effect you can feel. Mechanism is a hypothesis, not a result.

540 mg, measured against what you already eat

Here is the arithmetic that decides how seriously to take a BCAA line on a cognitive label, and it takes about ten seconds.

BCAAs are not exotic. They are ordinary constituents of dietary protein, abundant in meat, eggs, dairy, fish and legumes. A cross-sectional dietary survey of 300 older Iranian adults published in Scientific Reports reported mean total BCAA intake of 12.86 g/day, made up of roughly 5.5 g leucine, 4.0 g valine and 3.3 g isoleucine. A 2023 review in Advances in Nutrition similarly put leucine intake in well-nourished populations at about 5.6 to 6.9 g/day. Two different sources, converging on the same order of magnitude.

Supplemental dose against dietary background

That last row is the honest answer to "why are BCAAs in a brain supplement". At 540 mg, a 2:1:1 blend supplies about 270 mg of leucine — somewhere near four or five percent of what a person eating normally already consumes before breakfast has finished. It is not a pharmacological dose. It is not close to one. It cannot plausibly shift the LAT1 competition in a way that food does not already dominate.

Which is not the same as saying it is pointless. Amino acids serve as a nutrient base in a capsule, they are cheap and well tolerated, and they round out a formula. But the honest framing is nutritional, not cognitive.

What the evidence does not show

We would rather state the limits plainly than let them sit implied.

It does not show that BCAAs improve memory, focus or mental clarity in healthy adults. No trial has tested that question at a supplemental oral dose. Absence of evidence is not evidence of absence, but it is also not permission to claim a benefit.

It does not show that the brain injury findings apply to anyone else. Those patients were depleted, hospitalised, receiving an intravenous infusion roughly thirty-six times the size of a capsule dose, and being measured on a disability scale. Every one of those differences breaks the transfer.

It does not show that the neurotransmitter mechanism is beneficial. Reducing brain uptake of tryptophan and tyrosine is a real consequence of raising BCAAs, and it is not self-evidently a good thing. Fernstrom flagged the dose-response and adverse-effect thresholds as open questions two decades ago.

And it does not show anything about a finished blend. Memopezil's formula has never been tested as a finished product; only individual ingredients have been trialled, at their own isolated doses. That constraint applies to the BCAAs here exactly as it applies to the botanicals we cover in our review of what the bacopa and rhodiola evidence actually supports. If you want the general method for testing a label amount against a trial dose, we set it out in our guide to proprietary blends and named doses.

So why do they keep appearing on nootropic labels?

Three reasons, none of them sinister and none of them a trial result.

First, the mechanism is genuinely publishable. "Crosses the blood-brain barrier and influences serotonin and catecholamine synthesis" is a true sentence with real citations behind it, and it reads impressively on a website. Second, amino acids are inexpensive, stable and well tolerated, which makes them attractive filler mass in a capsule that also has to carry botanical extracts. Third, BCAAs carry positive associations from the sports supplement market, where they have been sold for decades.

The formulation logic is defensible. The marketing logic is where it goes wrong. If you are assessing a cognitive supplement, weight your judgement on the ingredients that have controlled human trials at the dose on the label — for this category that means bacopa monnieri and L-theanine first, with adaptogens behind them. Our week-by-week bacopa timeline covers what those trials actually measured and when. You can see the full disclosed panel on the Memopezil overview and judge the amounts for yourself.

Frequently asked questions